Cargando…
Correction: Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis
Autores principales: | Mokhtari, Reza Bayat, Qorri, Bessi, Baluch, Narges, Sparaneo, Angelo, Fabrizio, Federico Pio, Muscarella, Lucia Anna, Tyker, Albina, Kumar, Sushil, Cheng, Hai-Ling Margaret, Szewczuk, Myron R., Das, Bikul, Yeger, Herman |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450989/ https://www.ncbi.nlm.nih.gov/pubmed/36093295 http://dx.doi.org/10.18632/oncotarget.28104 |
Ejemplares similares
-
Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis
por: Mokhtari, Reza Bayat, et al.
Publicado: (2021) -
Human bronchial carcinoid tumor initiating cells are targeted by the combination of acetazolamide and sulforaphane
por: Bayat Mokhtari, Reza, et al.
Publicado: (2019) -
Combination of carbonic anhydrase inhibitor, acetazolamide, and sulforaphane, reduces the viability and growth of bronchial carcinoid cell lines
por: Mokhtari, Reza Bayat, et al.
Publicado: (2013) -
3D Multicellular Stem-Like Human Breast Tumor Spheroids Enhance Tumorigenicity of Orthotopic Xenografts in Athymic Nude Rat Model
por: Mokhtari, Reza Bayat, et al.
Publicado: (2021) -
The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy
por: Mokhtari, Reza Bayat, et al.
Publicado: (2021)